Here are three things to know:
- The acquisition deal includes an upfront payment of approximately $360 million for the 90% of SoniVie not already owned by Boston Scientific, with an additional $180 million contingent on regulatory milestones, according to a March 1 news release from the company.
- The TIVUS system uses ultrasound energy to target nerve activity linked to hypertension, potentially offering an alternative or adjunct to existing blood pressure treatments.
- The acquisition is expected to close in the first half of 2025 and is pending regulatory approval.
